Nanomedicine on the move: From monotherapeutic regimens to combination therapies

Expert Review of Clinical Pharmacology

Volumn 5, Issue 2, 2012, Pages 105-108

  Lammers, Twan ^a,b,c  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF TWENTE   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

cancer; chemotherapy; combination therapy; drug targeting; nanomedicine; radiotherapy

Indexed keywords

AMINOGLUTETHIMIDE; BEVACIZUMAB; CETUXIMAB; CISPLATIN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ERLOTINIB; FLOXURIDINE; GEFITINIB; GEMCITABINE; IRINOTECAN; PACLITAXEL POLIGLUMEX; SORAFENIB; SUNITINIB; TRASTUZUMAB; VINCRISTINE; VORINOSTAT;

ALOPECIA; BONE MARROW DEPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOMYOPATHY; CHEMORADIOTHERAPY; COLORECTAL CANCER; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; ESOPHAGUS CANCER; HUMAN; KAPOSI SARCOMA; LEUKEMIA; MONOTHERAPY; MULTIPLE MYELOMA; NANOMEDICINE; NAUSEA; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; STOMACH CANCER;

COMBINED MODALITY THERAPY; DRUG THERAPY; DRUG THERAPY, COMBINATION; HUMANS; NANOMEDICINE; NEOPLASMS;

EID: 84858427028     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.12.3     Document Type: Review

References (24)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 144, 646-674 (2011).
2. Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: principles and practice. Br. J. Cancer 99, 392-397 (2008).
3. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7, 653-664 (2010).
4. Wankhede M, Bouras A, Kaluzova M, Hadjipanayis CG. Magnetic nanoparticles: An emerging technology for malignant brain tumor imaging and therapy. Expert Rev. Clin Pharmacol. 5(2), 173-186 (2012).
5. Lammers T. Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations. Adv. Drug Deliv. Rev. 62, 203-230 (2010).
6. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumour vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control Release 65, 271-284 (2000).
7. Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J. Control Release 153, 198-205 (2011).
8. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J. Control Release doi:10.1016/j.jconrel.2011.09.063 (2011) (Epub ahead of print).
9. Greco F, Vicent MJ. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliv. Rev. 61, 1203-1213 (2009).
10. Dicko A, Mayer LD, Tardi PG. Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo. Expert Opin. Drug Deliv. 7, 1329-1341 (2010).
11. Lammers T, Subr V, Ulbrich K, Hennink WE, Storm G, Kiessling F. Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy. Nano Today 5, 197-212 (2010).
12. Harrington KJ, Rowlinson-Busza G, Syrigos KN et al. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clin. Cancer Res. 6, 4939-4949 (2000).
13. Davies CL, Lundstrom LM, Frengen J et al. Radiation improves the distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts. Cancer Res. 64, 547-553 (2004).
14. Li C, Ke S, Wu QP et al. Tumor irradiation enhances the tumor-specific distribution of poly(l-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. Clin. Cancer Res. 6, 2829-2834 (2000).
15. Lammers T, Subr V, Peschke P et al. Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy. Br. J. Cancer 99, 900-910 (2008).
16. Lammers T, Peschke P, Kühnlein R et al. Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems. J. Control Release 117, 333-341 (2007).
17. Lammers T, Subr V, Ulbrich K et al. Long-circulating and passively tumor-targeted polymer-drug conjugates improve the efficacy and reduce the toxicity of radiochemotherapy. Adv. Eng. Mater. 12, B413-B421 (2010).
18. Lammers T, Subr V, Ulbrich K et al.HPMA-based polymer therapeutics improve the efficacy of surgery, of radiotherapy and of chemotherapy combinations. Nanomedicine 5, 1501-1523 (2010).
19. Dipetrillo T, Milas L, Evans D et al. Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: A Phase 1 study. Am. J. Clin. Oncol. 29, 376-379 (2006).
20. Vicent MJ, Greco F, Nicholson RI, Paul A, Griffiths PC, Duncan R. Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew. Chem. Int. Ed. 44, 4061-4066 (2005).
21. Lammers T, Subr V, Ulbrich K et al. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 30, 3466-3475 (2009).
22. Sengupta S, Eavarone D, Capila I et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436, 568-572 (2005).
23. Feldman EJ, Lancet JE, Kolitz JE et al. First-in-man study of CPX-351: A liposomal carrier containing cytarabine and daunorubicin in a 5:1 molar ratio for the treatment of acute myeloid leukemia. J. Clin. Oncol. 29, 979-985 (2011).
24. Batist G, Gelmon KA, Chi KN et al. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin. Cancer Res. 15, 692-700 (2009).